Hints and tips:
...That, at least, was the allegation made by Northwest Biotherapeutics in a suit filed against seven broker-dealers including Virtu and Ken Griffin’s Citadel Securities in late 2022....
...J&J chief executive Joaquin Duato said the acquisition provided “a unique opportunity to accelerate our impact in cardiovascular intervention and drive greater value for patients, shareholders and health...
...Molnupiravir, marketed by Merck and co-developed with US biotech group Ridgeback Biotherapeutics, works by inducing small mutations in the virus itself....
...Maryland-based Northwest Biotherapeutics has a market capitalisation of about $860mn and is traded on the US over-the-counter market. Its shares currently change hands at about $0.83....
...Merck, which developed molnupiravir with partner Ridgeback Biotherapeutics, said it was in active discussions with regulators with the aim of bringing the drug to patients in Europe as quickly as possible...
...Farh said PrimateAI-3D was 12 per cent more accurate overall than any previous method of assessing genetic risks of developing health problems such as cardiovascular disease and type 2 diabetes....
...The WHO earlier this year said consumers should avoid sweeteners altogether because evidence suggests they do not reduce body fat and may be linked to an increased risk of type 2 diabetes, cardiovascular...
...New Jersey-based J&J said the Abiomed deal would broaden its medical technology division and hone its focus on cardiovascular disease....
...Johnson & Johnson thinks there is money to be made in the cardiovascular field....
...Johnson & Johnson announced in November it had struck a deal to acquire cardiovascular technology group Abiomed for $16.6bn, while Pfizer said in May it had agreed to buy US biotech Biohaven Pharmaceuticals...
...So will other unlikely possibilities, like a stomach ulcer or a cardiovascular disorder. After an unpleasant few hours, you’ll probably be sent home with an indigestion tablet....
...Molnupiravir, co-developed with Ridgeback Biotherapeutics and also known as Lagevrio, has been approved for use in the UK. European regulators are also reviewing it....
...He expects Chinese pharma companies to produce other types of innovative drugs that tackle other health problems that disproportionately affect the country’s domestic population such as cardiovascular disease...
...It really rounds out and complements our cardiovascular pipeline . . . and broadens and bolsters the overall pipeline,” Davis told the Financial Times....
...Developers Merck and Ridgeback Biotherapeutics expect it to pack a powerful punch. The release of unexpectedly good trial results sent shares in the US pharma group soaring at the start of the month....
...Last week Merck, which co-developed the antiviral pill with Ridgeback Biotherapeutics, said it expected molnupiravir to generate up to $7bn in global revenue by the end of next year....
...Under the licensing deal struck by Merck, its partner Ridgeback Biotherapeutics and Emory University with MPP, no royalties will be paid while the World Health Organization continues to classify Covid-19...
...Merck has already applied to the FDA for authorisation for an antiviral pill it developed in partnership with Ridgeback Biotherapeutics....
...It has also sought emergency authorisation for its drug, which was developed with Ridgeback Biotherapeutics....
...Late stage trials have shown the Pfizer pill, called Paxlovid, cuts the risk of hospitalisation and death by almost 90 per cent and a drug developed by Merck/MSD and Ridgeback Biotherapeutics cut the risk...
...Merck is developing the antiviral treatment in partnership with Ridgeback Biotherapeutics, a small Miami-based biotech company run by a wife-and-husband team....
...True, PMI sees opportunities to use inhaler technology to deliver cardiovascular or pain management drugs, or indeed other consumer products....
...One study of people who shopped regularly at Japanese konbini found that they tended to eat fewer fruits and vegetables or grains and pulses, and were more prone to cardiovascular disease....
...It accomplishes this by showing people how their cardiovascular health compares to the norms expected within their age bracket, with an estimate of their inner heart age and an indication of whether it is...
...It said it may have interim data for its oral drug, developed with Ridgeback Biotherapeutics, in the first quarter, and expected to have more than 10m courses produced by the end of 2021....
International Edition